Crystal structure of the human 5-HT1B serotonin receptor bound to an inverse agonist

Abstract5-hydroxytryptamine (5-HT, also known as serotonin) regulates many physiological processes through the 5-HT receptor family. Here we report the crystal structure of 5-HT1B subtype receptor (5-HT1BR) bound to the psychotropic serotonin receptor inverse agonist methiothepin (MT). Crystallization was facilitated by replacing ICL3 with a novel optimized variant of BRIL (OB1) that enhances the formation of intermolecular polar interactions, making OB1 a potential useful tool for structural studies of membrane proteins. Unlike the agonist ergotamine (ERG), MT occupies only the conserved orthosteric binding pocket, explaining the wide spectrum effect of MT on serotonin receptors. Compared with ERG, MT shifts toward TM6 and sterically pushes residues W3276.48, F3306.50 and F3316.51 from inside the orthosteric binding pocket, leading to an outward movement of the extracellular end and a corresponding inward shift of the intracellular end of TM6, a feature shared by other reported inactive G protein-coupled receptor (GPCR) structures. Together with the previous agonist-bound serotonin receptor structures, the inverse agonist-bound 5-HT1BR structure identifies a basis for the ligand-mediated switch of 5-HT1BR activity and provides a structural understanding of the inactivation mechanism of 5-HT1BR and some other class A GPCRs, characterized by ligand-induced outward movement of the extracellular end of TM6 that is coupled with inward movement of the cytoplasmic end of this helix.

[1]  R. McGuffin,et al.  Molecular cloning and functional characterization of a human 5-HT1B serotonin receptor: a homologue of the rat 5-HT1B receptor with 5-HT1D-like pharmacological specificity. , 1992, Biochemical and biophysical research communications.

[2]  T. Branchek,et al.  Human serotonin 1D receptor is encoded by a subfamily of two distinct genes: 5-HT1D alpha and 5-HT1D beta. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[3]  M. Erlander,et al.  A novel adenylyl cyclase-activating serotonin receptor (5-HT7) implicated in the regulation of mammalian circadian rhythms , 1993, Neuron.

[4]  D. Sibley,et al.  Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. , 1993, Molecular pharmacology.

[5]  R. Hen,et al.  The mouse 5-hydroxytryptamine 1B receptor is localized predominantly on axon terminals , 1994, Neuroscience.

[6]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.

[7]  P. Pauwels.  5-HT 1B/D receptor antagonists. , 1997, General pharmacology.

[8]  F. Monsma,et al.  Functional and Radioligand Binding Characterization of Rat 5-HT6 Receptors Stably Expressed in HEK293 Cells , 1997, Neuropharmacology.

[9]  P. Pauwels,et al.  How Efficacious are 5-HT1B/D Receptor Ligands: an Answer from GTPγS Binding Studies with Stably Transfected C6-glial Cell Lines , 1997, Neuropharmacology.

[10]  P. Pauwels,et al.  Activation of constitutive 5-hydroxytryptamine(1B) receptor by a series of mutations in the BBXXB motif: positioning of the third intracellular loop distal junction and its G(o)alpha protein interactions. , 1999, The Biochemical journal.

[11]  Johnson Gw,et al.  Present and future of 5-HT receptor agonists as antimigraine drugs. , 1999 .

[12]  P. Pauwels,et al.  Present and future of 5-HT receptor agonists as antimigraine drugs. , 1999, Clinical neuropharmacology.

[13]  K. Longenecker,et al.  Protein crystallization by rational mutagenesis of surface residues: Lys to Ala mutations promote crystallization of RhoGDI. , 2001, Acta crystallographica. Section D, Biological crystallography.

[14]  J. Ballesteros,et al.  Beta2 adrenergic receptor activation. Modulation of the proline kink in transmembrane 6 by a rotamer toggle switch. , 2002, The Journal of biological chemistry.

[15]  K. Longenecker,et al.  The impact of Glu-->Ala and Glu-->Asp mutations on the crystallization properties of RhoGDI: the structure of RhoGDI at 1.3 A resolution. , 2002, Acta crystallographica. Section D, Biological crystallography.

[16]  B. Roth,et al.  Molecular biology of serotonin receptors structure and function at the molecular level. , 2002, Current topics in medicinal chemistry.

[17]  A. Slassi.  Recent advances in 5-HT1B/1D receptor antagonists and agonists and their potential therapeutic applications. , 2002, Current topics in medicinal chemistry.

[18]  M. Millan,et al.  h5‐HT1B receptor‐mediated constitutive Gαi3‐protein activation in stably transfected Chinese hamster ovary cells: an antibody capture assay reveals protean efficacy of 5‐HT , 2003, British journal of pharmacology.

[19]  P. Saxena,et al.  Migraine: pathophysiology, pharmacology, treatment and future trends. , 2003, Current vascular pharmacology.

[20]  B. Roth,et al.  Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia , 2004, Nature Reviews Drug Discovery.

[21]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[22]  Jan H. Jensen,et al.  Very fast empirical prediction and rationalization of protein pKa values , 2005, Proteins.

[23]  F. Weigend.  Accurate Coulomb-fitting basis sets for H to Rn. , 2006, Physical chemistry chemical physics : PCCP.

[24]  T. Schwartz,et al.  Molecular mechanism of 7TM receptor activation--a global toggle switch model. , 2006, Annual review of pharmacology and toxicology.

[25]  P. Vekilov,et al.  Entropy and surface engineering in protein crystallization. , 2006, Acta crystallographica. Section D, Biological crystallography.

[26]  Andrei L. Lomize,et al.  OPM: Orientations of Proteins in Membranes database , 2006, Bioinform..

[27]  R. Stevens,et al.  GPCR Engineering Yields High-Resolution Structural Insights into β2-Adrenergic Receptor Function , 2007, Science.

[28]  R. Stevens,et al.  High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. , 2007, Science.

[29]  B. Roth.  Drugs and valvular heart disease. , 2007, The New England journal of medicine.

[30]  Z. Derewenda,et al.  Protein crystallization by surface entropy reduction: optimization of the SER strategy. , 2007, Acta crystallographica. Section D, Biological crystallography.

[31]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[32]  Brian M. Smith,et al.  Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity. , 2008, Journal of medicinal chemistry.

[33]  R. Stevens,et al.  Stabilization of the human beta2-adrenergic receptor TM4-TM3-TM5 helix interface by mutagenesis of Glu122(3.41), a critical residue in GPCR structure. , 2008, Journal of molecular biology.

[34]  V. Cherezov,et al.  Crystallizing membrane proteins using lipidic mesophases , 2009, Nature Protocols.

[35]  Steven O. Smith,et al.  Multiple switches in G protein-coupled receptor activation. , 2009, Trends in pharmacological sciences.

[36]  B. Roth,et al.  The expanded biology of serotonin. , 2009, Annual review of medicine.

[37]  W. Kabsch.  XDS , 2010, Acta crystallographica. Section D, Biological crystallography.

[38]  P. Emsley,et al.  Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.

[39]  Wolfgang Kabsch,et al.  Integration, scaling, space-group assignment and post-refinement , 2010, Acta crystallographica. Section D, Biological crystallography.

[40]  Michael Levitt,et al.  Super-resolution biomolecular crystallography with low-resolution data , 2010, Nature.

[41]  R. Abagyan,et al.  Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists , 2010, Science.

[42]  Randy J. Read,et al.  Acta Crystallographica Section D Biological , 2003 .

[43]  F. Neese,et al.  Efficient time-dependent density functional theory approximations for hybrid density functionals: analytical gradients and parallelization. , 2011, The Journal of chemical physics.

[44]  S. Rasmussen,et al.  Crystal Structure of the β2Adrenergic Receptor-Gs protein complex , 2011, Nature.

[45]  R. Stevens,et al.  Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor. , 2011, Journal of medicinal chemistry.

[46]  VINCENT ZOETE,et al.  SwissParam: A fast force field generation tool for small organic molecules , 2011, J. Comput. Chem..

[47]  Maria F. Sassano,et al.  Automated design of ligands to polypharmacological profiles , 2012, Nature.

[48]  R. Stevens,et al.  Structural Basis for Allosteric Regulation of GPCRs by Sodium Ions , 2012, Science.

[49]  Qiang Zhao,et al.  Ice breaking in GPCR structural biology , 2012, Acta Pharmacologica Sinica.

[50]  J. Shiloach,et al.  Structure of the agonist-bound neurotensin receptor , 2012, Nature.

[51]  Frank Neese,et al.  The ORCA program system , 2012 .

[52]  A. Kruse,et al.  Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist , 2011, Nature.

[53]  Joshua M. Kunken,et al.  Fusion partner toolchest for the stabilization and crystallization of G protein-coupled receptors. , 2012, Structure.

[54]  L. Pardo,et al.  Crystal structure of the μ-opioid receptor bound to a morphinan antagonist , 2012, Nature.

[55]  R. Stevens,et al.  Structure-function of the G protein-coupled receptor superfamily. , 2013, Annual review of pharmacology and toxicology.

[56]  R. Stevens,et al.  Structural Features for Functional Selectivity at Serotonin Receptors , 2013, Science.

[57]  Jing Huang,et al.  CHARMM36 all‐atom additive protein force field: Validation based on comparison to NMR data , 2013, J. Comput. Chem..

[58]  Hualiang Jiang,et al.  Structural Basis for Molecular Recognition at Serotonin Receptors , 2013, Science.

[59]  M. Babu,et al.  Molecular signatures of G-protein-coupled receptors , 2013, Nature.

[60]  F. Dimaio,et al.  Improved low-resolution crystallographic refinement with Phenix and Rosetta , 2014 .

[61]  E. Ross,et al.  G Protein-Coupled Receptors , 2019 .

[62]  Salvage or recovery of failed targets by mutagenesis to reduce surface entropy. , 2014, Methods in molecular biology.

[63]  Steven M. Moss,et al.  Structure of the human P2Y12 receptor in complex with an antithrombotic drug , 2014, Nature.

[64]  W. Weis,et al.  Modified T4 Lysozyme Fusion Proteins Facilitate G Protein-Coupled Receptor Crystallogenesis. , 2014, Structure.

[65]  Garth J. Williams,et al.  Crystal structure of rhodopsin bound to arrestin by femtosecond X-ray laser , 2014, Nature.

[66]  Matthieu Chavent,et al.  Epock: rapid analysis of protein pocket dynamics , 2014, Bioinform..

[67]  Berk Hess,et al.  GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers , 2015 .

[68]  Hualiang Jiang,et al.  Two disparate ligand-binding sites in the human P2Y1 receptor , 2015, Nature.

[69]  P. Kolb,et al.  Crystal structure of the human OX2 orexin receptor bound to the insomnia drug suvorexant , 2014, Nature.

[70]  Thomas J Lane,et al.  MDTraj: a modern, open library for the analysis of molecular dynamics trajectories , 2014, bioRxiv.

[71]  Xi-Ping Huang,et al.  Structure-Based Discovery of Novel and Selective 5-Hydroxytryptamine 2B Receptor Antagonists for the Treatment of Irritable Bowel Syndrome. , 2016, Journal of medicinal chemistry.

[72]  Ben M. Webb,et al.  Comparative Protein Structure Modeling Using MODELLER , 2016, Current protocols in bioinformatics.

[73]  A. J. Venkatakrishnan,et al.  Diverse activation pathways in class A GPCRs converge near the G-protein-coupling region , 2016, Nature.

[74]  A. Leslie,et al.  Structure of the adenosine A2A receptor bound to an engineered G protein , 2016, Nature.

[75]  R. Stevens,et al.  Crystal Structure of the Human Cannabinoid Receptor CB1 , 2016, Cell.

[76]  D. E. Nichols,et al.  Crystal Structure of an LSD-Bound Human Serotonin Receptor , 2017, Cell.

[77]  M. T. B. Geller,et al.  Molecular , 2019, Modern Pathology.